NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Fundamental Analysis
Europe - BIT:1NBIX - US64125C1099 - Common Stock
120.05 EUR
+120.05 (+Infinity%)
Taking everything into account, 1NBIX scores 7 out of 10 in our fundamental rating. 1NBIX was compared to 77 industry peers in the Biotechnology industry. 1NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1NBIX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make 1NBIX a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
1NBIX had positive earnings in the past year.
In the past year 1NBIX had a positive cash flow from operations.
In the past 5 years 1NBIX has always been profitable.
1NBIX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.95%, 1NBIX belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
1NBIX has a Return On Equity of 12.93%. This is amongst the best in the industry. 1NBIX outperforms 85.53% of its industry peers.
1NBIX has a Return On Invested Capital of 10.85%. This is amongst the best in the industry. 1NBIX outperforms 86.84% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1NBIX is in line with the industry average of 13.32%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.93% | ||
| ROIC | 10.85% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
The Profit Margin of 1NBIX (13.88%) is better than 80.26% of its industry peers.
In the last couple of years the Profit Margin of 1NBIX has grown nicely.
Looking at the Operating Margin, with a value of 19.89%, 1NBIX belongs to the top of the industry, outperforming 81.58% of the companies in the same industry.
1NBIX's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 98.49%, 1NBIX belongs to the best of the industry, outperforming 96.05% of the companies in the same industry.
1NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.89% | ||
| PM (TTM) | 13.88% | ||
| GM | 98.49% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1NBIX is still creating some value.
Compared to 1 year ago, 1NBIX has more shares outstanding
Compared to 5 years ago, 1NBIX has more shares outstanding
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
1NBIX has an Altman-Z score of 8.40. This indicates that 1NBIX is financially healthy and has little risk of bankruptcy at the moment.
1NBIX has a better Altman-Z score (8.40) than 82.89% of its industry peers.
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.4 |
ROIC/WACC1.16
WACC9.33%
2.3 Liquidity
A Current Ratio of 3.20 indicates that 1NBIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.20, 1NBIX is in the better half of the industry, outperforming 65.79% of the companies in the same industry.
1NBIX has a Quick Ratio of 3.10. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
1NBIX's Quick ratio of 3.10 is fine compared to the rest of the industry. 1NBIX outperforms 64.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.11% over the past year.
1NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
Looking at the last year, 1NBIX shows a quite strong growth in Revenue. The Revenue has grown by 18.42% in the last year.
1NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.48% yearly.
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%
3.2 Future
The Earnings Per Share is expected to grow by 36.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.22% on average over the next years. This is quite good.
EPS Next Y37.76%
EPS Next 2Y41.82%
EPS Next 3Y37.15%
EPS Next 5Y36.58%
Revenue Next Year18.64%
Revenue Next 2Y16.67%
Revenue Next 3Y14.97%
Revenue Next 5Y12.22%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
1NBIX is valuated quite expensively with a Price/Earnings ratio of 41.11.
Based on the Price/Earnings ratio, 1NBIX is valued a bit cheaper than 75.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.91. 1NBIX is valued rather expensively when compared to this.
1NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 21.03.
Based on the Price/Forward Earnings ratio, 1NBIX is valued cheaply inside the industry as 81.58% of the companies are valued more expensively.
1NBIX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.11 | ||
| Fwd PE | 21.03 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1NBIX is valued a bit cheaper than the industry average as 72.37% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1NBIX is valued a bit cheaper than the industry average as 78.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.11 | ||
| EV/EBITDA | 22.96 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of 1NBIX may justify a higher PE ratio.
1NBIX's earnings are expected to grow with 37.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.09
PEG (5Y)0.7
EPS Next 2Y41.82%
EPS Next 3Y37.15%
5. Dividend
5.1 Amount
No dividends for 1NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1NBIX (10/13/2025, 7:00:00 PM)
120.05
+120.05 (+Infinity%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner ChangeN/A
Ins Owners1.01%
Ins Owner ChangeN/A
Market Cap11.91B
Revenue(TTM)2.51B
Net Income(TTM)348.30M
Analysts83.53
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.31%
Min EPS beat(2)-85.62%
Max EPS beat(2)7%
EPS beat(4)1
Avg EPS beat(4)-33.29%
Min EPS beat(4)-85.62%
Max EPS beat(4)7%
EPS beat(8)2
Avg EPS beat(8)-28.41%
EPS beat(12)3
Avg EPS beat(12)-78.74%
EPS beat(16)4
Avg EPS beat(16)-77.91%
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)3.28%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)3.28%
Revenue beat(8)4
Avg Revenue beat(8)1.07%
Revenue beat(12)6
Avg Revenue beat(12)0.68%
Revenue beat(16)8
Avg Revenue beat(16)0.67%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.11 | ||
| Fwd PE | 21.03 | ||
| P/S | 5.5 | ||
| P/FCF | 26.11 | ||
| P/OCF | 24.33 | ||
| P/B | 5.12 | ||
| P/tB | 5.19 | ||
| EV/EBITDA | 22.96 |
EPS(TTM)2.92
EY2.43%
EPS(NY)5.71
Fwd EY4.75%
FCF(TTM)4.6
FCFY3.83%
OCF(TTM)4.93
OCFY4.11%
SpS21.83
BVpS23.43
TBVpS23.11
PEG (NY)1.09
PEG (5Y)0.7
Graham Number39.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.93% | ||
| ROCE | 14.93% | ||
| ROIC | 10.85% | ||
| ROICexc | 15.33% | ||
| ROICexgc | 15.57% | ||
| OM | 19.89% | ||
| PM (TTM) | 13.88% | ||
| GM | 98.49% | ||
| FCFM | 21.06% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score7
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 135.44% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.53% | ||
| Profit Quality | 151.79% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 8.4 |
F-Score7
WACC9.33%
ROIC/WACC1.16
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
EPS Next Y37.76%
EPS Next 2Y41.82%
EPS Next 3Y37.15%
EPS Next 5Y36.58%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%
Revenue Next Year18.64%
Revenue Next 2Y16.67%
Revenue Next 3Y14.97%
Revenue Next 5Y12.22%
EBIT growth 1Y-8.37%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.85%
FCF growth 1Y88.28%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y91.53%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ
What is the fundamental rating for 1NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
ChartMill assigns a valuation rating of 5 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Fairly Valued.
How profitable is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for 1NBIX stock?
The financial health rating of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 8 / 10.
Can you provide the expected EPS growth for 1NBIX stock?
The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 37.76% in the next year.